Histone Deacetylase Inhibitors in Cancer Therapy

Abstract excerpt

Histone deacetylase inhibitors (HDAC inhibitors) represent a novel class of antineoplastic agents that act by promoting acetylation of histones, leading in turn to uncoiling of chromatin and activation of a variety of genes implicated in the regulation of cell surivival, proliferation, differentiation, and apoptosis. The major classes of HDIs include shortchain fatty acids, hydroxamic acid derivatives, synthetic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Histone Deacetylase Inhibitors Research
• Share to Peptidase Inhibition and Analysis
• Share to Protein Degradation and Inhibitors